Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

How Neuroplasticity Changes with Age

Neuroplasticity declines with age, but research in animal models and human studies shows that the capacity for adaptive change persists. This page summarizes evidence on age-related neuroplasticity from laboratory and cl

peptides-pro Editorial

How Neuroplasticity Changes with Age

Neuroplasticity is the nervous system's capacity to reorganize its structure and function in response to experience, injury, or training. It encompasses synaptic plasticity, axonal sprouting, dendritic remodeling, and network-level reorganization. Age-related changes in neuroplasticity are observed across species and are characterized by a reduced capacity for adaptive remodeling, particularly after injury. The molecular and cellular mechanisms underlying these changes are the subject of ongoing research.

Research into age-related neuroplasticity centers on pathways including the corticospinal tract, neurotrophic signaling, and neuroimmune interactions. The following sections summarize studies that have examined specific mechanisms, models, and interventions relevant to neuroplasticity and aging.

Research Studies

OSKTFs and corticospinal axon sprouting in aged mice after stroke

In a mouse model of photothrombotic ischemic stroke, ectopic expression of a cocktail of transcription factors (Oct4, Sox2, and Klf4, referred to as OSKTFs) in adult corticospinal neurons reset developmental decline of epigenetic signatures without affecting spinal projection patterns or skilled locomotion. Corticospinal expression of OSKTFs had moderate effects on promoting collateral sprouting of corticospinal tract axons and recovery of skilled motor function. When combined with task-dependent rehabilitation, the effects on sprouting and recovery were enhanced [5]. This study was conducted in mice; findings may not translate directly to humans.

Cerebrolysin and language recovery in post-stroke aphasia

A case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis following an ischemic stroke. Despite timely thrombolysis and mechanical thrombectomy, she experienced significant neurological deficits. Early multidisciplinary rehabilitation combined with a 10-day course of Cerebrolysin was associated with recovery [4]. A separate randomized, placebo-controlled, double-blinded, single-center study is investigating the effects of Cerebrolysin on language ability in non-fluent aphasia patients after stroke, using PK-WAB scores to compare an experimental group receiving Cerebrolysin plus speech therapy with a control group receiving speech therapy alone [7]. These studies focus on post-stroke recovery, not directly on age-related decline.

Incretin therapy and exercise in type 2 diabetes: brain health outcomes

A clinical study is examining changes in brain and physical health in adults with type 2 diabetes who are initiating incretin-mimetic therapy (e.g., Ozempic, Mounjaro) and determining whether adding structured exercise provides additional benefits. Participants are randomized to receive incretin-mimetic therapy alone or incretin-mimetic therapy plus a structured exercise program for 24 weeks. Brain health is assessed through cognitive performance, mental health, and brain-mediated appetite measures [1]. This study is ongoing; results are not yet available.

Intermittent theta burst stimulation and neuroplasticity biomarkers in treatment-resistant depression

Intermittent theta burst stimulation (iTBS) is a non-invasive neuromodulation technique targeting the left dorsolateral prefrontal cortex. A single-center, prospective, investigator-initiated clinical study is investigating the effects of iTBS on clinical symptoms, executive functions, and peripheral inflammatory and neuroprotective biomarkers in patients with treatment-resistant depression [2]. The study aims to clarify biological mechanisms underlying treatment response. This research is in adults with depression and does not directly address age-related changes in neuroplasticity.

Psilocybin and neuroplasticity markers in major depressive disorder

A randomized controlled clinical trial is evaluating the effectiveness of psilocybin and psilocybin-assisted cognitive behavioral therapy (CBT) in the management of major depressive disorder (MDD). The study compares psilocybin-only therapy, CBT, and psilocybin-assisted CBT on depression symptoms, neurochemical markers, inflammatory markers, and neuroplasticity in individuals with MDD. Participants continue their routine depression medications and are assessed for changes in depression scores, biochemical markers, and brain activity patterns [8]. This study is ongoing; results are not yet available.

Gut Proteobacteria glycine metabolism and neuroplasticity in mice

In mice, cocaine exposure alters the composition of the gut microbiome, increasing the abundance of Proteobacteria. This microbial shift leads to a depletion in host glycine levels, altering cocaine-induced transcriptional changes in the nucleus accumbens (NAc) and facilitating the development of behavioral sensitization and reinstatement of cocaine self-administration [3]. The study links gut microbial metabolism to neuroplasticity-related behaviors in a mouse model. These findings are animal-only and may not extrapolate to humans.

Cytokines and neuroplasticity modulators in spinal canal stenosis

Lumbar spinal stenosis (LSS) is a degenerative musculoskeletal disorder characterized by narrowing of the spinal canal. A clinical study is investigating cytokines, neuroplasticity modulators, and biomarkers in LSS and endoscopic decompression. Histological changes in hypertrophied ligamentum flavum include fibrocartilaginous metaplasia, type II collagen proliferation, ossification, calcium crystal deposition, and degeneration of elastic and collagen fibers [6]. This study focuses on a specific degenerative condition and its surgical treatment, not on normal aging.

Exercise-induced neuroadaptation in stress regulation and emotional disorders

A review reports that exercise is increasingly recognized as a biologically active stimulus that may influence stress-responsive neural systems across molecular, autonomic, neurochemical, neuroimmune, and network levels. Evidence from human intervention studies and neuroimaging is summarized [10]. This reference-only item supports the broader context of neuroplasticity modulation but is not a primary study of age-related changes.

Osteopontin in aging-related neurological disorders

Osteopontin (encoded by secreted phosphoprotein 1) is a multifunctional matricellular phosphoglycoprotein that has emerged as an important mediator in the aging nervous system. During aging, osteopontin interacts with microglial priming, vascular remodeling, myelin repair, and innate immune responses [11]. This reference-only review highlights a molecular player in age-related neuroplasticity changes but does not present original experimental data.

Neuroimmune pharmacotherapy across the skin-brain axis

The skin-brain axis is a bidirectional neuroimmune network linking cutaneous inflammation with central neuroinflammation, stress signaling, and behavioral disturbances. A review summarizes mechanisms underlying skin-brain communication and evaluates pharmacological strategies targeting this axis [9]. This reference-only item provides context for neuroimmune contributions to neuroplasticity but is not specific to aging.

Fixed-dose combination CGXNW in spinal cord injury

A prospective, single-center, randomized, controlled, parallel-arm clinical trial involving 120 patients with subacute spinal cord injury randomized participants (1:1) to receive standard care alone or standard care plus a fixed-dose combination of inosine monophosphate, agmatine sulphate, and L-carnosine (CGXNW) for 6 months. Neurological recovery and functional independence were assessed [12]. This reference-only trial addresses spinal cord injury, not age-related neuroplasticity per se.

If you are reading this for personal health reasons

The materials and compounds discussed on this page are sold for laboratory research use only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp